Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.

Purdue MP, Lan Q, Martinez-Maza O, Oken MM, Hocking W, Huang WY, Baris D, Conde B, Rothman N.

Blood. 2009 Sep 24;114(13):2730-2. doi: 10.1182/blood-2009-04-217521. Epub 2009 Jul 28.

2.

Soluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts.

Bassig BA, Shu XO, Koh WP, Gao YT, Purdue MP, Butler LM, Adams-Haduch J, Xiang YB, Kemp TJ, Wang R, Pinto LA, Zheng T, Ji BT, Hosgood HD, Hu W, Yang G, Zhang H, Chow WH, Kim C, Seow WJ, Zheng W, Yuan JM, Lan Q, Rothman N.

Int J Cancer. 2015 Dec 1;137(11):2688-95. doi: 10.1002/ijc.29637. Epub 2015 Jun 26.

3.

Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population.

Vermeulen R, Hosnijeh FS, Portengen L, Krogh V, Palli D, Panico S, Tumino R, Sacredote C, Purdue M, Lan Q, Rothman N, Vineis P.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1925-7. doi: 10.1158/1055-9965.EPI-11-0396. Epub 2011 Jul 22.

4.

Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.

Purdue MP, Lan Q, Bagni R, Hocking WG, Baris D, Reding DJ, Rothman N.

Cancer Res. 2011 Jul 15;71(14):4898-907. doi: 10.1158/0008-5472.CAN-11-0165. Epub 2011 Jun 1.

5.

Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.

Hosnijeh FS, Portengen L, Späth F, Bergdahl IA, Melin B, Mattiello A, Masala G, Sacerdote C, Naccarati A, Krogh V, Tumino R, Chadeau-Hyam M, Vineis P, Vermeulen R.

Int J Cancer. 2016 May 15;138(10):2357-67. doi: 10.1002/ijc.29969. Epub 2016 Jan 8.

6.

Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.

Purdue MP, Lan Q, Kemp TJ, Hildesheim A, Weinstein SJ, Hofmann JN, Virtamo J, Albanes D, Pinto LA, Rothman N.

Leukemia. 2015 Jun;29(6):1429-31. doi: 10.1038/leu.2015.2. Epub 2014 Jan 8. No abstract available.

7.

B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS.

Grulich AE, Wan X, Law MG, Milliken ST, Lewis CR, Garsia RJ, Gold J, Finlayson RJ, Cooper DA, Kaldor JM.

AIDS. 2000 Jan 28;14(2):133-40.

PMID:
10708283
8.

A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers.

Lim U, Freedman DM, Hollis BW, Horst RL, Purdue MP, Chatterjee N, Weinstein SJ, Morton LM, Schatzkin A, Virtamo J, Linet MS, Hartge P, Albanes D.

Int J Cancer. 2009 Feb 15;124(4):979-86. doi: 10.1002/ijc.23984.

9.

[Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].

Iaguzhinskaia OE, Lazarev IE, Nikitin EA, Samoĭlova RS, Loginova IV, Gemdzhan EG, Novikov VA, Mamiliaeva ZKh, Pivnik AV.

Ter Arkh. 2001;73(4):45-51. Russian.

PMID:
11494447
10.

Markers of microbial translocation and risk of AIDS-related lymphoma.

Marks MA, Rabkin CS, Engels EA, Busch E, Kopp W, Rager H, Goedert JJ, Chaturvedi AK.

AIDS. 2013 Jan 28;27(3):469-74. doi: 10.1097/QAD.0b013e32835c1333.

PMID:
23169327
11.

Soluble cytokine receptor CD30 in atopic disorders: a case-control study.

Latza U, Davis S, Wilhelm D, McKnight B, Seyfarth M, Stein H.

Clin Exp Allergy. 1999 Jan;29(1):97-104.

PMID:
10051708
12.

A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.

Purdue MP, Hofmann JN, Kemp TJ, Chaturvedi AK, Lan Q, Park JH, Pfeiffer RM, Hildesheim A, Pinto LA, Rothman N.

Blood. 2013 Aug 8;122(6):951-7. doi: 10.1182/blood-2013-01-481077. Epub 2013 Jun 27. Erratum in: Blood. 2014 May 1;123(18):2901.

13.

Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.

De Roos AJ, Mirick DK, Edlefsen KL, LaCroix AZ, Kopecky KJ, Madeleine MM, Magpantay L, Martínez-Maza O.

Cancer Res. 2012 Sep 15;72(18):4733-43. Epub 2012 Jul 30.

14.

Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.

Edlefsen KL, Martínez-Maza O, Madeleine MM, Magpantay L, Mirick DK, Kopecky KJ, LaCroix AZ, De Roos AJ.

Int J Cancer. 2014 Aug 15;135(4):913-22. doi: 10.1002/ijc.28724. Epub 2014 Feb 3.

15.

A nested case-control study of non-Hodgkin lymphoma and serum organochlorine residues.

Rothman N, Cantor KP, Blair A, Bush D, Brock JW, Helzlsouer K, Zahm SH, Needham LL, Pearson GR, Hoover RN, Comstock GW, Strickland PT.

Lancet. 1997 Jul 26;350(9073):240-4.

PMID:
9242800
16.

Age-dependent changes of serum soluble CD30 concentration in children.

Chrul S, Polakowska E.

Pediatr Transplant. 2011 Aug;15(5):515-8. doi: 10.1111/j.1399-3046.2011.01516.x. Epub 2011 Jun 15.

PMID:
21672104
17.

Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma.

Breen EC, Fatahi S, Epeldegui M, Boscardin WJ, Detels R, Martínez-Maza O.

Tumour Biol. 2006;27(4):187-94. Epub 2006 Apr 27.

PMID:
16651853
18.

Can serum soluble CD23 or CD30 predict the occurrence of lymphoma in HIV-infected patients?

Jarrin I, Boval B, Mazeron MC, Simoneau G, Magnier JD, Green A, Andreoli A, Bergmann JF, Sellier P.

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):e58-61. doi: 10.1097/QAI.0b013e31821dbbcf. No abstract available.

PMID:
21860351
19.

High serum level of soluble CD30 in acute primary HIV-1 infection.

Pizzolo G, Vinante F, Nadali G, Krampera M, Morosato L, Chilosi M, Raiteri R, Sinicco A.

Clin Exp Immunol. 1997 May;108(2):251-3.

20.

Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2.

Velásquez SY, García LF, Opelz G, Alvarez CM, Süsal C.

Transplantation. 2013 Jul 27;96(2):154-61. doi: 10.1097/TP.0b013e318296fd69.

PMID:
23857000

Supplemental Content

Support Center